Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance

Zeng, Zhijun; Yang, Lian-Yue; Ding, Xiang; Wang, Wei

doi:10.3748/wjg.v10.i23.3414

Cited by 51 publications

(40 citation statements)

References 37 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 High CTGF expression is closely associated with metastasis and a poor prognosis in several cancers. 26,27 In contrast, several other studies have reported a relation between the overexpression of CTGF and cancer inhibition. 28,29 Interestingly, CTGF induces apoptosis in MCF-7 cells and aortic smooth muscle cells.…”

Section: Discussionmentioning

confidence: 71%

Id-1gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer

2005

View full text Add to dashboard Cite

The molecular mechanisms underlying the chemopreventive effects of NSAIDs are not well understood and remain the subject of debate. One of the mechanistic possibilities involves alterations in gene expression. We examined gene expression profiles in SNU601 gastric cancer cells treated with sulindac sulfide (50 lM) for 24 hr. Microarray analysis showed that 1.3% (105/8170) of genes were induced or repressed more than 3-fold in cells treated with sulindac sulfide. Seven genes were selected and confirmed by reverse transcription-polymerase chain reaction. Inhibitor of differentiation/DNA binding-1 (Id-1) was downregulated in SNU601 cells treated with sulindac sulfide. Id-1 expression level was decreased dose-dependently by sulindac sulfide. In addition, the expression pattern of Id-1 was inversely related to that of nm23. We also examined Id-1 expression in human gastric cancer tissues and compared it with clinicopathologic parameters to study its biologic role in the cancers. Id-1 was frequently and strongly expressed in gastric cancer tissues compared with that in adjacent nonmetaplastic mucosa. Its immunoreactivity scores were positively correlated to Ki67 labeling indices and tumor progression, and is higher in intestinal type than in diffuse type. In summary, a number of genes, both induced and repressed, could be important in mediating sulindac sulfide-induced cell death in gastric cancer cells. Id-1, one of the repressed genes, is upregulated in gastric cancers and has positive role in tumor progression and histogenesis of intestinal-type cancers. ' 2005 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 71%

Id-1gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer

2005

View full text Add to dashboard Cite

show abstract

“…A reduction in the CTGF level of CT26 cells after stable transfection with antisense CTGF resulted in increased liver metastasis in BALB/c mice [31]. A further study from Zeng et al [32] shows that CTGF genes may play an important role in hepatocellular carcinogenesis and correlate with recurrence and metastasis of hepatocellular carcinoma. In conclusion, our study demonstrates a higher mRNA expression of HGF in untreated liver tissue 48 hours after hepatic resection and a higher mRNA expression of CTGF in untreated tumor tissue 96 hours up to 14 days after LITT, which was associated with a reduced tumor growth at day 14 compared to hepatic resection and an untreated control group.…”

Section: Discussionmentioning

confidence: 99%

Laser‐induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection

et al. 2006

View full text Add to dashboard Cite

Background and Objectives: Proliferation and synthesis of hepatocellular tissue after tissue damage are promoted by specific growth factors such as hepatic tissue growth factor (HGF) and connective growth factor (CTGF). Laser-induced thermotherapy (LITT) for the treatment of liver metastases is deemed to be a parenchyma-saving procedure compared to hepatic resection. The aim of this study was to compare the impact of LITT and hepatic resection on intrahepatic residual tumor tissue and expression levels of mRNA HGF/CTGF within liver and tumor tissue. Study Design/Materials and Methods: Two independent adenocarcinomas (CC531) were implanted into 75 WAG rats, one in the right (untreated tumor) and one in the left liver lobe (treated tumor). The left lobe tumor was treated either by LITT or partial hepatectomy. The control tumor was submitted to in-situ hybridization of HGF and CTGF 24-96 hours and 14 days after intervention. Results: Volumes of the untreated tumors prior to intervention were 38 AE 8 mm 3 in group I (laser), 39 AE 7 mm 3 in group II (resection), and 42 AE 12 mm 3 in group III (control) and did not differ significantly (P > 0.05). Fourteen days after the intervention the mean tumor AE SEM volume of untreated tumor in group I (laser) [223 AE 36] was smaller than in group II (resection) [1233.28 AE 181.52; P < 0.001], and in group III (control) [978.92 AE 87.57; P < 0.003]. Forty-eight hours after the intervention intrahepatic mRNA expression level of HGF in group II (resection) was almost twofold higher than in group I (laser) [7.2 AE 1.0 c/mf vs. 3.9 AE 0.4 c/mf; P < 0.01]. Fourteen days after the intervention intrahepatic mRNA expression level of CTGF in group I (laser) was higher than in group II (resection) [13.89 AE 0.77 c/mf vs. 9.09 AE 0.78 c/mf; P < 0.003]. Conclusions: LITT leads to a decrease of residual tumor growth in comparison to hepatic resection. Accelerated tumor growth after hepatic resection is associated with higher mRNA level of HGF and reduced tumor growth after LITT with higher mRNA level of CTGF. The increased CTGF-mediated regulation of ECM may cause reduced residual tumor growth after LITT.

show abstract

“…Elevated CTGF levels have been detected in a number of cancers including pancreatic (15), breast (16), glioblastoma (17,18), esophageal (19), melanoma (20), chondrosarcoma (21), oral squamous cell cancer (22), acute lymphoblastic leukemia (23), rhabdomyosarcoma (24), and hepatocellular carcinoma (25), but its direct role in tumor suppression or progression has not been investigated in pancreatic cancer nor with therapeutic agents with the capacity to inhibit CTGF function in vivo. An increase in CTGF was reported to be associated with decreased survival of patients with breast cancer (16), glioblastoma (18), or adenocarcinoma of the esophagus (19), and increased breast cancer bone metastasis in a mouse model (26).…”

Section: Introductionmentioning

confidence: 99%

Connective Tissue Growth Factor–Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor Growth and Metastasis

et al. 2006

View full text Add to dashboard Cite

Pancreatic cancer is highly aggressive and refractory to most existing therapies. Past studies have shown that connective tissue growth factor (CTGF) expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer cell lines. To address whether and how CTGF influences tumor growth, we generated pancreatic tumor cell lines that overexpress different levels of human CTGF. The effect of CTGF overexpression on cell proliferation was measured in vitro in monolayer culture, suspension culture, or soft agar, and in vivo in tumor xenografts. Although there was no effect of CTGF expression on proliferation in two-dimensional cultures, anchorage-independent growth (AIG) was enhanced. The capacity of CTGF to enhance AIG in vitro was linked to enhanced pancreatic tumor growth in vivo when these cells were implanted s.c. in nude mice. Administration of a neutralizing CTGF-specific monoclonal antibody, FG-3019, had no effect on monolayer cell proliferation, but blocked AIG in soft agar. Consistent with this observation, anti-CTGF treatment of mice bearing established CTGF-expressing tumors abrogated CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity observed in normal tissue. Together, these studies implicate CTGF as a new target in pancreatic cancer and suggest that inhibition of CTGF with a human monoclonal antibody may control primary and metastatic tumor growth. (Cancer Res 2006; 66(11): 5816-27)

show abstract

Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance

Cited by 51 publications

References 37 publications

Id-1gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer

Id-1gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer

Laser‐induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection

Connective Tissue Growth Factor–Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor Growth and Metastasis

Contact Info

Product

Resources

About